The short version of LC-MS/MS fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2025-07-18. Anything still debated is marked as such rather than presented as settled.
Regulatory treatment of SR9009 reflects its investigational status. The compound has no approved human therapeutic indication, and sports authorities prohibit its use. It appears on anti-doping lists as a non-approved substance or metabolic modulator, depending on the list version. Products sold online as research chemicals are not quality-controlled medicines, so their identity and purity can differ from the label. Such products may also contain unlisted compounds, which complicates both testing and safety assessment.
Scientific discussion of SR9009 often separates animal evidence from human anecdote. Rodent studies provide controlled data on endurance, metabolism, and gene expression, but they use specific strains, doses, and treatment durations. Human reports are mostly uncontrolled and cannot establish cause and effect. Open questions include oral bioavailability, tissue distribution, metabolic stability, and long-term effects. Review articles generally call for more rigorous pharmacokinetic and safety research before any clinical use could be considered.
Analytical methods for SR9009 typically rely on liquid chromatography coupled with tandem mass spectrometry. The technique can separate the parent compound from related substances and detect low concentrations in biological matrices. Urine and blood are common samples in anti-doping testing, while in vitro studies may use cell culture media. Rapid metabolism and low expected concentrations make method validation important for reliable identification. Exact metabolite patterns can vary by species and are not fully mapped.
In laboratory settings, SR9009 is commonly identified by its molecular structure and its interaction with REV-ERB receptors. Vendors may list it under synonyms such as Stenabolic or REV-ERB agonist, but those names do not define purity or identity. Analytical confirmation typically uses high-performance liquid chromatography with ultraviolet detection or liquid chromatography–mass spectrometry. A reference standard is needed to compare retention time and mass spectrum, because the compound can be confused with related research chemicals.
Handling practices for SR9009 focus on minimizing degradation and contamination. The solid is generally stored desiccated at or below -20 °C, protected from light and moisture. Stock solutions are often prepared in dimethyl sulfoxide or ethanol, then aliquoted to avoid repeated freeze–thaw cycles. Aqueous solubility is low, so formulations for animal studies may require cosolvents or suspending agents. Personnel should follow institutional chemical safety procedures, because toxicological data for humans are incomplete.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved for human use | Investigational status in most countries |
| Sports status | Prohibited by WADA | Classified as non-approved or metabolic modulator |
| Common analytical method | LC-MS/MS | Used for trace detection in biological samples |
| Typical test matrices | Urine and blood | Sample choice depends on testing program |
| Human trial data | None published | Effects and safety are not established |
Laboratory samples of SR9009 are typically supplied as a white to off-white powder. The compound dissolves readily in organic solvents such as dimethyl sulfoxide and ethanol, while its solubility in water is low. Because of this solubility profile, researchers often prepare concentrated stock solutions in an organic solvent before diluting them into aqueous assay buffers. Light exposure, moisture, and repeated freeze-thaw cycles can degrade many small molecules, so handling procedures usually aim to minimize these factors. Purity is commonly checked before use.
Storage conditions for research-grade SR9009 generally involve a freezer at approximately minus twenty degrees Celsius, sometimes lower for long-term preservation. Containers should remain tightly closed and protected from light. Desiccants may be used to limit moisture uptake. Solutions are often stored in aliquots to avoid repeated warming and cooling. Stability data for the compound under various conditions are limited, so laboratories typically follow supplier recommendations and verify performance through periodic analytical checks rather than assuming indefinite stability.
Identity and purity testing for SR9009 commonly uses liquid chromatography coupled with tandem mass spectrometry. This method separates the compound from matrix components and detects it by mass-to-charge transitions, providing sensitive and specific confirmation. Nuclear magnetic resonance spectroscopy can support structural identification, while high-performance liquid chromatography with ultraviolet detection may estimate purity. Because online products labeled as SR9009 may contain other substances or no active compound at all, independent verification is important in research settings. Certificates of analysis are useful but not a substitute for in-house testing.
Laboratory samples of SR9009 are typically handled as research chemicals rather than pharmaceuticals. Suppliers usually state that the material is for research use only and not for human or veterinary administration. Storage recommendations generally call for a freezer at approximately −20 °C, protection from light, and a desiccated environment. The solid is often described as a white to off-white powder. Solubility is commonly reported in organic solvents such as dimethyl sulfoxide and ethanol, with low solubility in water.
Analytical identification and purity assessment often use high-performance liquid chromatography with ultraviolet detection or mass spectrometry. Liquid chromatography–tandem mass spectrometry is used to detect and quantify SR9009 in biological matrices, including urine and blood, for anti-doping or pharmacokinetic studies. Nuclear magnetic resonance spectroscopy can confirm molecular structure. Stability depends on form and storage: the solid is generally more stable than solutions, and repeated freeze–thaw cycles may degrade samples. Purity is typically reported as a percentage from a certificate of analysis.
SR9009 binds REV-ERB receptors and alters their repressive activity on target genes. This action can change transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. In rodent studies, treated animals have shown changes in muscle oxidative capacity and exercise performance, though effects vary by dose, duration, and model. The precise molecular steps connecting receptor binding to whole-body outcomes are still an active area of investigation. Findings in animals do not automatically translate to humans.
Because REV-ERB receptors are core clock components, SR9009 has been examined for effects on daily rhythms as well as metabolism. Research has explored whether the compound can shift or reinforce circadian gene expression in tissues such as liver and muscle. Some studies report improved metabolic markers in obese or diabetic mice, while others show context-dependent responses. Questions remain about which effects are direct, which are secondary to timing, and how they might differ across species.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not a steroid, peptide, or natural hormone. In scientific literature, it appears under the code SR9009 and in non-scientific contexts as Stenabolic. The compound was identified through chemical screening efforts aimed at targeting circadian clock components. Its status remains investigational, and no regulatory agency has approved it as a human medicine.
REV-ERB proteins help regulate daily cycles in gene expression, including genes tied to lipid and glucose metabolism. SR9009 binds these receptors and alters their activity in cell and animal experiments. Consequences observed in rodents include changes in skeletal muscle oxidative capacity, blood lipid levels, and exercise performance. The precise chain from receptor occupancy to whole-body effects is still an active area of study. Human responses cannot be assumed from rodent data.
Most published work on SR9009 consists of preclinical studies. It is widely sold as a research chemical, a category that does not imply safety, efficacy, or pharmaceutical-grade quality. Sports anti-doping organizations have listed SR9009 as a prohibited substance, and its presence in an athlete sample can lead to sanctions. Legal status differs by country; in several jurisdictions it is not approved for human consumption and may be treated as an unapproved new drug.
While advertising of tobacco products is banned in most countries, television and radio e-cigarette advertising in several countries may be indirectly encouraging traditional cigarette use. E-cigarette advertisements are also in magazines, newspapers, online, and in retail stores. Between 2010 and 2014, e-cigarettes were second only to cigarettes as the top advertised product in magazines. As cigarette companies have acquired the largest e-cigarette brands, they currently benefit from a dual market of smokers and e-cigarette users while simultaneously presenting themselves as agents of harm reduction. This raises concerns about the appropriateness of endorsing a product that directly profits the tobacco industry. There is no evidence that the cigarette brands are selling e-cigarettes as part of a plan to phase out traditional cigarettes, despite some stating to want to cooperate in "harm reduction". E-cigarette advertising for using e-cigarettes as a quitting tool have been seen in the US, UK, and China, which have not been supported by regulatory bodies. In the US, six large e-cigarette businesses spent $59.3 million on promoting e-cigarettes in 2013. In the US and Canada, over $2 million is spent yearly on promoting e-cigarettes online. E-cigarette websites often made unscientific health statements in 2012. The ease to get past the age verification system at e-cigarette company websites allows underage individuals to access and be exposed to marketing.
==== Yolk sac ==== The yolk sac is a membranous sac attached to an embryo, formed by cells of the hypoblast layer of the bilaminar embryonic disc. This is alternatively called the umbilical vesicle. In humans, the yolk sac is important in early embryonic blood supply.
== Background == Casey is of Mexican descent. A former Division I soccer player at the University of Texas at El Paso, Casey began training MMA in 2009 after her soccer career was cut short due to an injury. She began her amateur career in 2012, and her professional career a year later.
Sources: en.wikipedia.org
Vitacost.com, Inc. is an American e-commerce company based in Boca Raton, Florida, that sells vitamins, supplements and organic grocery products. The company was bought by Kroger in 2014. Vitacost was inducted into Inc Magazine's "Inc. 500 Lifetime Hall of Fame," in 2006 as one of the US's 500 fastest-growing privately held businesses for five consecutive years (2001–2005). The company was acquired by iHerb on 8 January, 2026.
Planned as an "adult release" (Japanese films were classified by the country's film board as "general release" or "adult"), the usual pace of production at Nikkatsu (10 days pre-production, 25 days shooting, three days post-production) allowed Suzuki and his innovative production designer Takeo Kimura precious little time to construct sets to recreate post-war firebombed Tokyo. Sets were slapped together on the backlot using materials purloined from studio warehouses, and theatrical set design techniques which could compromise the film's "realism." The resulting production has been lauded for its resulting visual flair. Most female actresses at Nikkatsu refused to work in the film due to the nudity and subject matter, so the cast's female roles were filled by actresses from outside the studio.
==== 1.A α-type channels ==== 1.A.1 Voltage-gated ion channel superfamily 1.A.2 Inward-rectifier K+ channel family 1.A.3 Ryanodine-inositol-1,4,5-trisphosphate receptor Ca2+ channel family 1.A.4 Transient receptor potential Ca2+ channel family 1.A.5 Polycystin cation channel family 1.A.6 Epithelial Na+ channel family 1.A.7 ATP-gated P2X receptor cation channel family 1.A.8 Major intrinsic protein superfamily 1.A.9 Neurotransmitter receptor, Cys loop, ligand-gated ion channel family 1.A.10 Glutamate-gated ion channel family of neurotransmitter receptors 1.A.11 Ammonium channel transporter family 1.A.12 Intracellular chloride channel family 1.A.13 Epithelial chloride channel family 1.A.14 Testis-enhanced gene transfer family 1.A.15 Nonselective cation channel-2 family 1.A.16 Formate-nitrite transporter family 1.A.17 Calcium-dependent chloride channel family 1.A.18 Chloroplast envelope anion-channel-forming Tic110 family 1.A.19 Type A influenza virus matrix-2 channel family 1.A.20 BCL2/Adenovirus E1B-interacting protein 3 family 1.A.21 Bcl-2 family 1.A.22 Large-conductance mechanosensitive ion channel 1.A.23 Small-conductance mechanosensitive ion channel 1.A.24 Gap-junction-forming connexin family 1.A.25 Gap-junction-forming innexin family 1.A.26 Mg2+ transporter-E family 1.A.27 Phospholemman family 1.A.28 Urea transporter family 1.A.29 Urea/amide channel family 1.A.30 H+- or Na+-translocating bacterial MotAB flagellar motor/ExbBD outer-membrane transport energizer superfamily 1.A.31 Annexin family 1.A.32 Type B influenza virus NB channel family 1.A.33 Cation-channel-forming heat shock protein 70 family 1.A.34 Bacillus gap junction-like channel-forming complex family 1.A.35 CorA metal ion transporter family 1.A.36 Intracellular chloride channel family 1.A.37 CD20 Ca2+ channel family 1.A.38 Golgi pH regulator family 1.A.39 Type C influenza virus CM2 channel family 1.A.40 Human immunodeficiency virus type I Vpu channel family 1.A.41 Avian reovirus p10 Vvroporin family 1.A.42 HIV viral protein R family 1.A.43 Camphor resistance or fluoride exporter family 1.A.44 Pore-forming tail Tip pb2 protein of phage T5 family 1.A.45 Phage P22 injectisome family 1.A.46 Anion channel-forming bestrophin family 1.A.47 Nucleotide-sensitive anion-selective channel, ICln family 1.A.48 Anion channel Tweety family 1.A.49 Human coronavirus ns12.9 viroporin family 1.A.50 Phospholamban (Ca2+-channel and Ca2+-ATPase regulator) family 1.A.51 The Voltage-gated Proton Channel (VPC) Family 1.A.52 The Ca2+ Release-activated Ca2+ (CRAC) Channel (CRAC-C) Family 1.A.53 The Hepatitis C Virus P7 Viroporin Cation-selective Channel (HCV-P7) Family 1.A.54 The Presenilin ER Ca2+ Leak Channel (Presenilin) Family 1.A.55 The Synaptic Vesicle-Associated Ca2+ Channel, Flower (Flower) Family 1.A.56 The Copper Transporter (Ctr) Family 1.A.57 The Human SARS Coronavirus Viroporin (SARS-VP) 1.A.58 The Type B Influenza Virus Matrix Protein 2 (BM2-C) Family 1.A.59 The Bursal Disease Virus Pore-Forming Peptide, Pep46 (Pep46) Family 1.A.60 The Mammalian Reovirus Pre-forming Peptide, Mu-1 (Mu-1) Family 1.A.61 The Insect Nodavirus Channel-forming Chain F (Gamma-Peptide) Family 1.A.62 The Homotrimeric Cation Channel (TRIC) Family 1.A.63 The Ignicoccus Outer Membrane α-helical Porin (I-OMP Family 1.A.64 The Plasmolipin (Plasmolipin) Family 1.A.65 The Coronavirus Viroporin E Protein (Viroporin E) Family 1.A.66 The Pardaxin (Pardaxin) Family 1.A.67 The Membrane Mg2+ Transporter (MMgT) Family 1.A.68 The Viral Small Hydrophobic Viroporin (V-SH) Family 1.A.69 The Heteromeric Odorant Receptor Channel (HORC) Family 1.A.70 The Molecule Against Microbes A (MamA) Family 1.A.71 The Brain Acid-soluble Protein Channel (BASP1 Channel) Family 1.A.72 The Mer Superfamily 1.A.73 The Colicin Lysis Protein (CLP) Family 1.A.74 The Mitsugumin 23 (MG23) Family 1.A.75 The Mechanical Nociceptor, Piezo (Piezo) Family 1.A.76 The Magnesium Transporter1 (MagT1) Family 1.A.77 The Mg2+/Ca2+ Uniporter (MCU) Family 1.A.78 The K+-selective Channel in Endosomes and Lysosomes (KEL) Family 1.A.79 The Cholesterol Uptake Protein (ChUP) or Double Stranded RNA Uptake Family 1.A.80 The NS4a Viroporin (NS4a) Family 1.A.81 The Low Affinity Ca2+ Channel (LACC) Family 1.A.82 The Hair Cell Mechanotransduction Channel (HCMC) Family 1.A.83 The SV40 Virus Viroporin VP2 (SV40 VP2) Family 1.A.84 The Calcium Homeostasis Modulator Ca2+ Channel (CALHM-C) Family 1.A.85 The Poliovirus 2B Viroporin (2B Viroporin) Family 1.A.86 The Human Papilloma Virus type 16 (HPV16) L2 Viroporin (L2 Viroporin) Family 1.A.87 The Mechanosensitive Calcium Channel (MCA) Family 1.A.88 The Fungal Potassium Channel (F-Kch) Family 1.A.89 The Human Coronavirus 229E Viroporin (229E Viroporin) Family 1.A.90 The Human Metapneumovirus (HMPV) Viroporin (HMPV-Viroporin) Family 1.A.91 The Cytoadherence-linked Asexual Protein 3.2 of Plasmodium falciparum (Clag3) Family 1.A.92 The Reovirus Viroporin VP10 (RVP10) Family 1.A.93 The Bluetongue Virus Non-Structural Protein 3 Viroporin (NS3) Family 1.A.94 The Rotavirus Non-structural Glycoprotein 4 Viroporin (NSP4) Family 1.A.95 The Ephemerovirus Viroporin (EVVP) Family 1.A.96 The Human Polyoma Virus Viroporin (PVVP) Family 1.A.97 The Human Papillomavirus type 16 E5 Viroporin (HPV-E5) Family 1.A.98 Human T-Lymphotropic Virus 1 P13 protein (HTLV1-P13) Family 1.A.99 The Infectious Bronchitis Virus Envelope Small Membrane Protein E (IBV-E) Family 1.A.100 The Rhabdoviridae Putative Viroporin, U5 (RV-U5) Family 1.A.101 The Peroxisomal Pore-forming Pex11 (Pex11) Family 1.A.102 Influenza A viroporin PB1-F2 (PB1-F2) Family 1.A.103 The Simian Virus 5 (Parainfluenza Virus 5) SH (SV5-SH) Family 1.A.104 The Proposed Flagellar Biosynthesis Na+ Channel, FlaH (FlaH) Family 1.A.105 The Mixed Lineage Kinase Domain-like (MLKL) Family 1.A.106 The Calcium Load-activated Calcium Channel (CLAC) Family 1.A.107 The Pore-forming Globin (Globin) Family
Sources: en.wikipedia.org
No. It is an investigational compound without approved therapeutic indications. It is sold for research purposes only in many jurisdictions.
Sports authorities prohibit it because it is not approved for human use and has potential performance-enhancing effects. It appears on anti-doping lists under non-approved or metabolic modulator categories.
Detection usually uses liquid chromatography-tandem mass spectrometry. The method targets the parent compound or its metabolites in urine or blood.
Liquid chromatography–mass spectrometry is common for identity and purity checks. High-performance liquid chromatography with ultraviolet detection can also be used. Both methods require a suitable reference standard.